Suresh K. Durgam Sells 7,344 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Suresh K. Durgam sold 7,344 shares of the company’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.04, for a total transaction of $330,773.76. Following the transaction, the executive vice president now owns 23,104 shares in the company, valued at $1,040,604.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $45.31 on Wednesday. The company has a market capitalization of $4.32 billion, a P/E ratio of -16.66 and a beta of 1.13. The company’s 50-day simple moving average is $48.16 and its two-hundred day simple moving average is $49.20. Intra-Cellular Therapies, Inc. has a one year low of $42.01 and a one year high of $66.00.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.17. Intra-Cellular Therapies had a negative net margin of 102.37% and a negative return on equity of 35.88%. The business had revenue of $87.87 million for the quarter, compared to the consensus estimate of $86.97 million. During the same period in the prior year, the firm earned ($1.05) EPS. The company’s revenue for the quarter was up 242.3% compared to the same quarter last year. On average, research analysts expect that Intra-Cellular Therapies, Inc. will post -2.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of ITCI. JPMorgan Chase & Co. boosted its stake in shares of Intra-Cellular Therapies by 11.7% during the first quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock valued at $9,615,000 after purchasing an additional 16,454 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Intra-Cellular Therapies by 5.2% during the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock valued at $23,591,000 after purchasing an additional 18,999 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Intra-Cellular Therapies during the first quarter valued at approximately $349,000. PNC Financial Services Group Inc. boosted its stake in shares of Intra-Cellular Therapies by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,204 shares in the last quarter. Finally, Natixis Advisors L.P. boosted its stake in shares of Intra-Cellular Therapies by 71.3% during the first quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 7,558 shares in the last quarter. 86.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ITCI has been the topic of several analyst reports. Mizuho cut their price target on shares of Intra-Cellular Therapies from $72.00 to $66.00 in a report on Friday, March 3rd. Needham & Company LLC reiterated a “buy” rating and set a $70.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, March 1st. JPMorgan Chase & Co. cut their price target on shares of Intra-Cellular Therapies from $59.00 to $58.00 and set an “overweight” rating on the stock in a report on Thursday, March 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $83.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, February 1st. Finally, Royal Bank of Canada cut their price target on shares of Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating on the stock in a report on Thursday, March 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $69.40.

About Intra-Cellular Therapies

(Get Rating)

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.